Cannabis Hyperemesis Syndrome Cases In Virginia ERs Up By Nearly 29%

Why It Matters

The spike in CHS admissions signals emerging strain on emergency services and underscores the need for clinicians and policymakers to address cannabis‑related health risks as legalization spreads.

Key Takeaways

• CHS ER visits rose 29% from 2020 to 2024.
• Total cannabis‑related ED visits average 31,000 annually in Virginia.
• Symptoms include vomiting, nausea, abdominal pain, and compulsive hot showers.
• Abstinence resolves CHS; supportive care manages acute episodes.

Pulse Analysis

Virginia’s emergency departments are grappling with a notable uptick in cannabis‑related encounters, driven largely by the emergence of cannabis hyperemesis syndrome (CHS). Data from the Virginia Hospital & Healthcare Association reveal a 29% increase in CHS diagnoses over a five‑year span, mirroring a broader rise in overall cannabis abuse, dependence, and poisoning cases. This pattern coincides with the state’s progressive legalization framework and the proliferation of high‑potency THC products, which extend exposure for frequent users and amplify the risk of chronic adverse effects.

Clinically, CHS presents a distinctive constellation of severe vomiting, persistent nausea, abdominal discomfort, and an unusual compulsion for hot showers that temporarily eases symptoms. While the exact pathophysiology remains elusive, research points to prolonged, heavy cannabis consumption—often initiated in adolescence—as a key risk factor. Diagnosis is challenging because symptoms overlap with other gastrointestinal disorders, leading to repeated emergency visits and extensive diagnostic workups. Awareness among emergency physicians is critical to differentiate CHS from more common causes of emesis and to initiate appropriate counseling.

Management hinges on cannabis cessation, which typically resolves the syndrome within weeks, supplemented by supportive measures such as intravenous hydration and anti‑emetic therapy. The growing burden on emergency services highlights a public‑health gap that policymakers must address through education campaigns, standardized screening protocols, and funding for targeted research. As legalization expands nationwide, proactive strategies will be essential to mitigate CHS incidence and safeguard both patients and healthcare resources.